Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that frontal fibrosing alopecia in postmenopausal women involves selective follicular inflammation, and finasteride treatment may slow disease progression, suggesting a potential androgen-related component.

Frontal fibrosing alopecia may be caused by an autoimmune reaction and hormonal imbalance.

This study found that oral tofacitinib led to variable hair regrowth in patients with resistant alopecia areata, implying that longer treatment durations may be needed to fully assess its effectiveness.

In this case report, a woman with Graham-Little-Piccardi-Lassueur Syndrome and hidradenitis suppurativa showed significant improvements in both conditions after six months of treatment with tofacitinib, a Janus Kinase inhibitor, with no recurrence or adverse events noted during a two-year follow-up.

This study observed that 70.7% of patients with frontal fibrosing alopecia stabilized with treatment, and patients using 0.3% tacrolimus were more likely to stabilize in 3 months compared to other treatments.

This study found that the Arabidopsis thaliana protein Formin 2 localizes to plasmodesmata and is crucial for regulating their permeability by anchoring actin filaments, which affects virus susceptibility.

This study found that women with female pattern hair loss exhibited hormonal imbalances, with the Free Androgen Index being a particularly effective diagnostic marker.

This study reports that tofacitinib, a JAK inhibitor, may stabilize hair loss in patients with classic lichen planopilaris and frontal fibrosing alopecia, though hair regrowth was not robust.

This article reports a case of frontal fibrosing alopecia in its early inflammatory stage that responded positively to intralesional steroid treatment.

This study discusses the role of CD8+ T-cell and interferon γ signaling in vitiligo's pathogenesis and notes that JAK inhibitors, which are FDA-approved for other autoimmune diseases, may offer a potential treatment path by blocking this pathway.

This study compared oral tofacitinib and methotrexate in treating moderate-to-severe alopecia areata, finding that tofacitinib was more effective at reducing SALT scores and improving scalp hair assessment PRO scores, though both treatments reduced psychological distress similarly without serious adverse effects.

Contact allergies might contribute to frontal fibrosing alopecia.

In this study, intralesional triamcinolone acetonide was associated with eyebrow regrowth in some patients with frontal fibrosing alopecia.

This review examined the common side effects of FGFR inhibitors like erdafitinib, pemigatinib, and futibatinib, and detailed strategies for managing them, highlighting that proactive monitoring and appropriate interventions can effectively mitigate these toxicities.

This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.

In this study, researchers identified a temperature-sensitive mutation in the FERONIA gene of plants that prevents root hair formation at elevated temperatures, highlighting its role in maintaining root hair growth and response to plant hormones.

This study in Morocco found that all women with frontal fibrosing alopecia presented frontotemporal hairline recession, with trichoscopic features such as perifollicular erythema and follicular hyperkeratosis being indicative of the condition, and suggested a potential link between cosmetic products or emotional factors and the disease.

This study presents a validated questionnaire, the FFA-QLI, which effectively assesses and differentiates the quality of life impact among patients with frontal fibrosing alopecia, showing greater sensitivity in identifying severe cases than the DLQI.

This paper presents consensus guidelines for standardized diagnostic criteria and assessment methods for frontal fibrosing alopecia to improve clinical research and data collection globally.

This study reviewed 18 postmenopausal women with frontal fibrosing alopecia, noting frontotemporal hairline recession and eyebrow loss, often treated with steroids, triamcinolone, and other medications.

This open-label study found that oral tofacitinib led to significant hair regrowth in patients with moderate-to-severe alopecia areata, supported by changes in gene expression and T cell dynamics.

This study reports that oral tofacitinib treatment in a patient with refractory lichen planus pigmentosus and frontal fibrosing alopecia resulted in near-complete resolution of hyperpigmentation and cessation of hairline recession over 18 months, and suggests it may be a promising therapy for these challenging conditions.

This study found that trichothiodystrophy can be diagnosed prenatally in the second trimester using an endoscopically-guided fetal eyebrow biopsy, with sulfur content analysis being the most reliable test.

Topical tofacitinib helped a man with severe scalp condition after other treatments failed.

In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.

This study identified that trichoscopy can effectively diagnose frontal fibrosing alopecia by highlighting specific scalp abnormalities in postmenopausal women.

This study found that a specific T-cell receptor motif associated with lipid-antigen stimulation may play a role in the pathogenesis of folliculotropic mycosis fungoides.

This study found that higher levels of the protein Flii were associated with enhanced hair follicle regeneration and longer hair fibers in a mouse model.

This article reviews frontal fibrosing alopecia, exploring its characteristics, demographics, and associated conditions, and calls for controlled trials due to an increase in worldwide cases; it reports no new findings.

This article contains additional supporting information available online but presents no new research findings.